By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – UK amplification firm Sirigen today announced it has raised about £3.8 million ($6.1 million) in two completed rounds of financing, which it will use to support commercialization of its High Sensitivity Fluorescence technology.

Leading the rounds was a syndicate of new investors including IQ Capital, the National Endowment for Science, Technology, and the Arts, and YFM Private Equity. Existing investors Seraphim Capital and Oxford Capital Partners also participated.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Helix customers can purchase apps that interpret different aspects of their genome, Technology Review reports.

The New York Times reports that a number of companies and research institutes are pursuing gene therapies.

Salmon with shorter telomeres survive to make the trip back to their river homes, New Scientist reports.

In PLOS this week: vaginal microbiome composition, population patterns of Chagas-carrying Rhodnius ecuadoriensis, and more.